/
Oncology
Neuroendocrine Carcinoma
45
Pipeline Programs↗
54
Active Trials↗
27
Companies Involved↗
Neuroendocrine Carcinoma is a moderately active landscape with 45 programs across 27 companies. The most active players are Suzhou Zelgen Biopharmaceuticals Co.,Ltd. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 17
Phase 228
Phase 34
Approved
No programs
Analysis
Modality Breakdown
62%
Small molecule
23 of 37 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 91% of 45 pipeline programs.
Analysis
Trial Status
115
clinical trials
Completed34 · 30%
Recruiting30 · 26%
Unknown status14 · 12%
Active, not recruiting12 · 10%
Not yet recruiting12 · 10%
Terminated8 · 7%
Other5 · 4%
Clinical Trials
Trial Activity
115 trials
A Single-arm, Open-label, Single-center Clinical Trial of Surufatinib and Serplulimab Combined With Standard Chemotherapy (Platinum/Etoposide) in Neuroendocrine Carcinoma.
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Preclinical·NCT05747729·60 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)